Medi-Cal supplemental rebate program not explicitly exempted from prohibition in conference Medicaid bill.
Executive Summary
MEDI-CAL SUPPLEMENTAL REBATE PROGRAM NOT EXPLICITLY EXEMPTED under the House/Senate conference agreement on the Budget Reconciliation Act (HR 2491), which received final passage by the House Nov. 20. The conference agreement provides that "no rebates shall be required to be paid by manufacturers with respect to covered outpatient drugs furnished to individuals in any State that provides for the collection of such rebates in excess of the rebate amount" of 15% of average manufacturer price or "best price," as provided in the bill ("The Pink Sheet" Nov. 20, p. 3).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth